Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 5/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1528006 | 1.00 | CSNK2B (0.44) | CSNK2BGPR119CDK2MAPKAPK2CSNK2A2 | |
| SCHEMBL1528003 | 1.00 | CSNK2B (0.44) | CSNK2BGPR119CDK2MAPKAPK2CSNK2A2 | |
| SCHEMBL12841221 | 0.93 | CSNK2B (0.41) | CSNK2BGPR119CDK2CSNK2A2CSNK2A1 | |
| SCHEMBL1487845 | 0.87 | KDM4E (0.38) | CSNK2BGPR119CDK2MAPKAPK2CSNK2A2 | |
| SCHEMBL1487847 | 0.87 | KDM4E (0.38) | CSNK2BGPR119CDK2MAPKAPK2CSNK2A2 | |
| SCHEMBL12768866 | 0.87 | CSNK2B (0.44) | CSNK2BCDK2MAPKAPK2 | |
| SCHEMBL1486079 | 0.85 | GPR119 (0.39) | CSNK2BGPR119CDK2MAPKAPK2CSNK2A2 | |
| SCHEMBL12768989 | 0.84 | CSNK2B (0.53) | CSNK2BCDK2CSNK2A2CSNK2A1 | |
| SCHEMBL12645965 | 0.79 | KDM4E (0.38) | CSNK2BGPR119CDK2CSNK2A2GPR6 | |
| SCHEMBL1487763 | 0.78 | CSNK2B (0.53) | CSNK2BCDK2CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2011031979-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | PIM2, PIM1, PIM3 | CSNK2B 17/4885GPR119 2782/4885CDK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.